Continuous XXXX infusion in the treatment of uncontrollable neonatal @entity410 .

@entity1 @entity410 @entity3175 @entity452 @entity935 @entity1372 @entity109 @entity3174 @entity460 @entity972 @entity551 @entity1363 @entity413
A prospective open-label study was designed to determine the efficacy and safety of continuous @entity1363 infusion in neonates with uncontrollable neonatal @entity410 . @entity1 whose @entity410 could not be controlled by @entity3175 , @entity3174 or @entity109 were enrolled. @entity1363 was given as an intravenous bolus dose followed by continuous intravenous infusion. Thirty-two @entity1 fulfilled the inclusion criteria. @entity1363 terminated the @entity410 in all @entity1 . The maximum dose of @entity1363 ranged from 1 microgram/kg/min to 15 micrograms/kg/min, with average of 4 micrograms/kg/min. Four @entity1 had recurrent @entity410 , which stop after @entity1363 was reinstituted. There were no significant changes in serum @entity1372 , @entity972 , @entity460 or @entity413 in any of the @entity1 . Adverse effects included @entity551 in 12 @entity1 (38%) that was successfully controlled with intropic agents ( @entity935 and/or @entity452 ) and transient urinary retention in 12 (38%). Our study suggests that @entity1363 is safe and effective for the treatment of uncontrollable neonatal @entity410 .
